SPRB Spruce Biosciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: SPRB

Price (delayed)

$49.415

Market cap

$142.02M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$39.78

Enterprise value

$53.06M

?
Relative Growth: Rel. Growth: 10
Relative Strength: Rel. Strength: 96
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 4
Highlights
The company's equity has surged by 142% QoQ
The company's quick ratio has surged by 91% QoQ
SPRB's EPS has surged by 54% year-on-year but it is down by 9% since the previous quarter
The revenue has plunged by 100% YoY
SPRB's gross profit has shrunk by 100% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.sprucebiosciences.com
Peers: AMGN GILD VRTX REGN

Key stats

What are the main financial stats of SPRB

SPRB stock price

How has the Spruce Biosciences stock price performed over time
Intraday
-1.15%
1 week
-8.76%
1 month
-4.2%
1 year
481.35%
YTD
-43.27%
QTD
-8.49%

Financial performance

How have Spruce Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$47.83M
Net income
-$51.35M
Gross margin
N/A
Net margin
N/A
The revenue has plunged by 100% YoY
SPRB's gross profit has shrunk by 100% YoY
Spruce Biosciences's operating income has decreased by 41% from the previous quarter but it has increased by 6% YoY
The net income has declined by 38% since the previous quarter and by 6% year-on-year

Price vs fundamentals

How does SPRB's price correlate with its fundamentals

Growth

What is Spruce Biosciences's growth rate over time

Valuation

What is Spruce Biosciences stock price valuation
P/E
N/A
P/B
1.62
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
SPRB's EPS has surged by 54% year-on-year but it is down by 9% since the previous quarter
The company's equity has surged by 142% QoQ
The stock's price to book (P/B) is 82% more than its 5-year quarterly average of 0.9 but 14% less than its last 4 quarters average of 1.9
The revenue has plunged by 100% YoY

Efficiency

How efficient is Spruce Biosciences business performance
The return on equity is up by 30% year-on-year and by 21% since the previous quarter
The return on assets is up by 24% year-on-year and by 11% since the previous quarter

Dividends

What is SPRB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SPRB.

Financial health

How did Spruce Biosciences financials performed over time
The total liabilities has soared by 121% YoY but it has contracted by 11% from the previous quarter
SPRB's current ratio has surged by 98% since the previous quarter
The company's debt is 91% lower than its equity
The company's equity has surged by 142% QoQ
Spruce Biosciences's debt to equity has shrunk by 55% QoQ and by 25% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.